Elena Garralda

Oct 8, 2024 | dailyreporter.esmo.org | Elena Garralda

Unleashing the true power of immunotherapy in oncology is still challenging. While immunotherapeutic strategies continue to transform the cancer treatment landscape by improving outcomes and the long-term outlook for many patients, only subsets of cancer patients currently derive benefit from them and response rates vary across different tumour types.

Jun 24, 2024 | dailyreporter.esmo.org | Elena Garralda

As we seek to push the boundaries in harnessing the immune system to more effectively treat cancer, important headway in early clinical trials in the neoadjuvant setting could also pave the way for practice-changing strategies to help a larger number of people with cancer.

Feb 28, 2024 | dailyreporter.esmo.org | Elena Garralda

For more than two decades, drug licensing in the US and Europe has permitted the use of surrogate endpoints in the approval of new therapies, largely based on biomarker discovery.

Nov 29, 2023 | dailyreporter.esmo.org | Elena Garralda

The pace of change in oncology is breathtaking. As we celebrate the myriad advances presented at the ESMO Congress 2023, with many practice-changing results from clinical trials such as MARIPOSA and MARIPOSA2, ALINA, PSMAfore, EV-302/KEYNOTE-A39, much work still needs to be done to collectively improve outcomes for an increasing number of our patients as we ring in the next generation of personalised medicine in oncology.

Jun 19, 2023 | dailyreporter.esmo.org | Elena Garralda

Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care In oncology, we are continuing to witness how disruptive study designs and genomically enriched trial strategies are dancing to the beat of precision oncology through the advent of master protocol trials, including basket and umbrella studies, that are progressively reshaping the landscape of drug development in oncology.